Essentials for Clinicians: Genitourinary Tract Tumours - Editors and Contributors

Editors

Johann de Bono
Division of Clinical Studies / Drug Development Unit / Prostate Cancer Targeted Therapies Group, Institute of Cancer Research, The Royal Marsden NHS Foundation Trust, London, UK

Silke Gillessen
Department of Oncology and Haematology, Kantonsspital St. Gallen (KSSG), St. Gallen, Switzerland

Niven Mehra
Division of Clinical Studies / Prostate Cancer Targeted Therapies Group, Institute of Cancer Research, The Royal Marsden NHS Foundation Trust, London, UK

Series editor: Michele Ghielmini
Oncology Institute of Southern Switzerland, Ospedale San Giovanni, Bellinzona, Switzerland

Contributors

Chapter 1 - Anatomy of the GU Tract and Histology of GU Tumours

S Minner - Institute for Pathology, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany

G Sauter - Institute for Pathology, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany

Chapter 2 - Staging and Treatment of Localised Prostate Cancer

N Clarke - Salford Royal Hospital and The Christie Hospitals, Manchester, UK

Chapter 3 - Treatment of Metastatic Prostate Cancer

A Omlin - Department of Oncology and Haematology, Kantonsspital St. Gallen (KSSG), St. Gallen, Switzerland

S Gillessen - Department of Oncology and Haematology, Kantonsspital St. Gallen (KSSG), St. Gallen, Switzerland

Chapter 4 - Staging and Treatment of Localised Bladder Cancer

G Gakis - Department of Urology, University Hospital Tübingen, Tübingen, Germany

A Stenzl - Department of Urology, University Hospital Tübingen, Tübingen, Germany

Chapter 5 - Metastatic Urothelial Bladder Cancer

A Sherif - Umeå University, Department of Surgical and Perioperative Sciences, Urology and Andrology, Umeå, Sweden

C Thellenberg Karlsson - Umeå University, Department of Radiation Sciences, Oncology, Umeå, Sweden

Chapter 6 - Staging and Treatment of Localised Renal Cell Cancer

A Volpe - Division of Urology, Maggiore della Carità Hospital, University of Eastern Piedmont, Novara, Italy

Chapter 7 - Treatment of Metastatic Renal Cell Cancer

M Schmidinger - Medical University of Vienna, Department of Medicine I and Cancer Center, Clinical Division of Oncology, Vienna, Austria

Chapter 8 - Staging and Treatment of Stage I Testicular Cancer

J Oldenburg - Department of Oncology, Akershus University Hospital, Lørenskog, Norway and University of Oslo, Norway

T Tandstad - The Cancer Clinic, St Olavs University Hospital, Trondheim, Norway

Chapter 9 - Treatment of Metastatic Germ Cell Tumour

K Fizazi - Department of Cancer Medicine, Institut Gustave Roussy, University of Paris Sud, Villejuif, France

C Massard - Department of Cancer Medicine, Institut Gustave Roussy, University of Paris Sud, Villejuif, France

Chapter 10 - Epidemiology, Risk Factors, and Screening for Prostate Cancer

FH Schröder - Erasmus University Medical Center, Department of Urology, Rotterdam, The Netherlands

Chapter 11 - Rare Tumours of Prostate, Kidney, Bladder, and Testis

E Senkus - Department of Oncology & Radiotherapy, Medical University of Gdańsk, Gdańsk, Poland

M Ligaj - Department of Pathology, M. Skłodowska-Curie Memorial Cancer Centre, Warsaw, Poland

Chapter 12 - Other Rare Tumours (Upper Tract Transitional Cell Carcinoma, Malignant Adrenal Tumours, Penile Cancer)

T Powles - Barts Cancer Institute, Queen Mary University of London, UK

MD Mediano - Virgen del Rocio University Hospital, Seville, Spain

N Mehra - Division of Clinical Studies / Prostate Cancer Targeted Therapies Group, Institute of Cancer Research, The Royal Marsden NHS Foundation Trust, London, UK

G Di Lorenzo - GU Cancer Section, Medical Oncology, AOU Federico II, Napoli, Italy

P Rescigno - Division of Clinical Studies / Prostate Cancer Targeted Therapies Group, Institute of Cancer Research, The Royal Marsden NHS Foundation Trust, London, UK

Chapter 13 - Hereditary Kidney Cancer Syndromes

A Bex - Division of Surgical Oncology, Department of Urology, Netherlands Cancer Institute, Amsterdam, The Netherlands

RH Giles - University Medical Center Utrecht, Department of Nephrology, Utrecht, The Netherlands

Chapter 14 - New Drugs and Novel Treatment Strategies for Prostate Cancer

J de Bono - Division of Clinical Studies / Drug Development Unit / Prostate Cancer Targeted Therapies Group, Institute of Cancer Research, The Royal Marsden NHS Foundation Trust, London, UK

N Mehra - Division of Clinical Studies / Prostate Cancer Targeted Therapies Group, Institute of Cancer Research, The Royal Marsden NHS Foundation Trust, London, UK

Chapter 15 - New Drugs and Novel Treatment Strategies for Kidney Cancer

L Albiges - Department of Cancer Medicine, Institut Gustave Roussy, University of Paris Sud, Villejuif, France

B Escudier - Department of Cancer Medicine, Institut Gustave Roussy, University of Paris Sud, Villejuif, France

Appendix 4: Selected Treatment Schedule

E Breen - Pharmacy Department, The Royal Marsden NHS Foundation Trust, London, UK

SM Tan - Pharmacy Department, The Royal Marsden NHS Foundation Trust, Sutton, UK

Declarations of Interest

L Albiges: No conflicts of interest.

A Bex: No conflicts of interest.

E Breen: No conflicts of interest.

N Clarke: No conflicts of interest.

J de Bono: Conducting research sponsored by companies including AstraZeneca, Astellas, Genentech, Janssen, Bayer, and others.

G Di Lorenzo: Advisory role: Janssen, Astellas, Sanofi, Pfizer, Novartis.

B Escudier: No conflicts of interest.

K Fizazi: No conflicts of interest.

G Gakis: No conflicts of interest.

RH Giles: No conflicts of interest.

S Gillessen: Advisory role: Astellas, Bayer, Curevac, Dendreon, Janssen Cilag, Jansen Diagnostics, Millennium, Novartis, Orion, Pfizer, Sanofi-Aventis, ProteoMedix (uncompensated); Speakers’ bureau (uncompensated): Amgen, Bayer, Janssen Cilag, Sanofi-Aventis.

M Ligaj: No conflicts of interest.

C Massard: No conflicts of interest.

MD Mediano: No conflicts of interest.

N Mehra: No conflicts of interest.

S Minner: No conflicts of interest.

J Oldenburg: No conflicts of interest.

A Omlin: Advisory role and travel support: Sanofi-Aventis, Bayer; Advisory role: Janssen, Astellas, AstraZeneca, Pfizer, Bayer.

T Powles: No conflicts of interest.

P Rescigno: No conflicts of interest.

G Sauter: No conflicts of interest.

M Schmidinger: Advisory role and honoraria for lectures: Novartis, Roche, Pfizer, Astellas, AVEO, BMS.

FH Schröder: No conflicts of interest.

E Senkus: No conflicts of interest.

A Sherif: No conflicts of interest.

A Stenzl: No conflicts of interest.

SM Tan: No conflicts of interest.

T Tandstad: No conflicts of interest.

C Thellenberg Karlsson: No conflicts of interest.

A Volpe: No conflicts of interest.

« Previous Page

Last update: 01 September 2015